Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:futibatinib
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:Japan
gptkb:United_States cholangiocarcinoma with FGFR2 fusion or rearrangement |
| gptkbp:ATCCode |
L01EX25
|
| gptkbp:brand |
Lytgobi
|
| gptkbp:CASNumber |
1440251-70-9
|
| gptkbp:chemicalFormula |
C26H20FN5O3
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Taiho_Pharmaceutical
|
| https://www.w3.org/2000/01/rdf-schema#label |
TAS-120
|
| gptkbp:indication |
cholangiocarcinoma
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
469.47 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue alopecia dry mouth hyperphosphatemia nail toxicity stomatitis |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR4 gptkb:FGFR2 |
| gptkbp:bfsParent |
gptkb:CD332
|
| gptkbp:bfsLayer |
7
|